Pulse Biosciences, Inc.
Pulse Biosciences pioneers in the research, design, and production of patented Nanosecond Pulsed Field Ablation™ (nsPFA™) technology for healthcare. Focused on cardiology, they aim to develop innovative treatments such as for atrial fibrillation, leveraging their CellFX® nsPFA™ platform to potentially revolutionize cardiac care and other therapy areas.
Industries
Nr. of Employees
medium (51-250)
Pulse Biosciences, Inc.
Patents
Products
Endocardial multielectrode ablation catheter (360-degree)
A multielectrode endocardial catheter system designed to deliver nanosecond-duration pulsed-field energy for rapid pulmonary vein isolation and endocardial ablation.
Surgical clamp for linear transmural ablation
A surgical clamp device engineered to deliver pulsed-field energy to create continuous linear transmural lesions during cardiac surgery.
Percutaneous electrode for non-cardiac ablation
A needle-style percutaneous electrode intended to deliver pulsed-field energy for targeted nonthermal ablation of cellular tissue in non-cardiac indications.
Endocardial multielectrode ablation catheter (360-degree)
A multielectrode endocardial catheter system designed to deliver nanosecond-duration pulsed-field energy for rapid pulmonary vein isolation and endocardial ablation.
Surgical clamp for linear transmural ablation
A surgical clamp device engineered to deliver pulsed-field energy to create continuous linear transmural lesions during cardiac surgery.
Percutaneous electrode for non-cardiac ablation
A needle-style percutaneous electrode intended to deliver pulsed-field energy for targeted nonthermal ablation of cellular tissue in non-cardiac indications.
Services
Support for investigator-led and company-sponsored clinical investigations, including organization of live procedural demonstrations and physician training.
Collaborative preclinical studies to evaluate lesion formation, safety and imaging correlates using pathological and microscopic analyses.
Preparation of regulatory documentation and support for investigational device use and device submissions to regulatory bodies.
Support for investigator-led and company-sponsored clinical investigations, including organization of live procedural demonstrations and physician training.
Collaborative preclinical studies to evaluate lesion formation, safety and imaging correlates using pathological and microscopic analyses.
Preparation of regulatory documentation and support for investigational device use and device submissions to regulatory bodies.
Expertise Areas
- Cardiac electrophysiology device development
- Clinical trial design and execution for cardiac ablation devices
- Preclinical cardiac and non-cardiac ablation research
- Regulatory strategy and 510(k) submission preparation
Key Technologies
- Nanosecond pulsed field ablation
- Multielectrode endocardial catheter design
- Percutaneous electrode ablation
- Surgical clamp for linear transmural ablation
News & Updates
Live case showcasing the nsPFA™ 360˚ Catheter’s ability to rapidly isolate the pulmonary veins, integrated with the CARTO™ 3 Mapping System from Johnson & Johnson, performed by Dr. Jan Petru and Dr. Moritoshi Funasako and moderated by Dr. Vivek Reddy, Dr. Petr Neuzil and Dr. Gregory Michaud.
Live case highlighting the nsPFA 360 Catheter’s ability to rapidly isolate the pulmonary veins with a fast, efficient workflow performed by Prof. Petr Neuzil and Drs Moritoshi Funasako and Jan Petru and moderated by Dr. Vivek Reddy.
Dr. David Kenigsberg joins Pulse Biosciences as Chief Medical Officer of Electrophysiology, a highly respected cardiac electrophysiologist.
Promising 60-day follow-up results from the initial patients treated in the feasibility study for atrial fibrillation, demonstrating favorable durability of pulmonary vein isolation.
Presentation on the application of CellFX® nsPFA™ Percutaneous Electrode in treating benign thyroid nodules, with 30 patients treated in the study.
Presentation on the CellFX® nsPFA™ 360 Cardiac Catheter at the 29th Annual AF Symposium 2024, highlighting its advantages over conventional devices.
Live case showcasing the nsPFA™ 360˚ Catheter’s ability to rapidly isolate the pulmonary veins, integrated with the CARTO™ 3 Mapping System from Johnson & Johnson, performed by Dr. Jan Petru and Dr. Moritoshi Funasako and moderated by Dr. Vivek Reddy, Dr. Petr Neuzil and Dr. Gregory Michaud.
Live case highlighting the nsPFA 360 Catheter’s ability to rapidly isolate the pulmonary veins with a fast, efficient workflow performed by Prof. Petr Neuzil and Drs Moritoshi Funasako and Jan Petru and moderated by Dr. Vivek Reddy.
Dr. David Kenigsberg joins Pulse Biosciences as Chief Medical Officer of Electrophysiology, a highly respected cardiac electrophysiologist.
Promising 60-day follow-up results from the initial patients treated in the feasibility study for atrial fibrillation, demonstrating favorable durability of pulmonary vein isolation.
Presentation on the application of CellFX® nsPFA™ Percutaneous Electrode in treating benign thyroid nodules, with 30 patients treated in the study.
Presentation on the CellFX® nsPFA™ 360 Cardiac Catheter at the 29th Annual AF Symposium 2024, highlighting its advantages over conventional devices.